549 - Clinical Characteristics and Outcomes of Patients with COVID-19 treated with Convalescent Plasma in Miami, Florida

The ePoster content is available to users who are logged in.<br><br>Please log in and then come back here to use this button.

Presenting Author(s)

Shweta Anjan

Assistant Professor of Clinical Medicine
University of Miami Miller School of Medicine and Miami Transplant Institute, Jackson Health System
Miami, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Co-Author(s)

DS

Dimitra Skiada

ID fellow
University of Miami Miller School of Medicine
miami, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
MD

Miriam Andrea Duque Cuartas

Assistant professor
University of Miami
Miami, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Douglas Salguero

Resident
Mount Sinai Medical Center
MIAMI, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
DS

David P. Serota

Assistant Professor of Clinical Medicine
University of Miami Miller School of Medicine
Miami, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Jose A. Gonzales-Zamora

Associate Professor
Infectious Disease Division. University of Miami, Miller School of Medicine.
Miami, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Folusakin Ayoade

Assistant Professor
University of Miami
Miami, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Laura Beauchamps

Associate Professor of Clinical Medicine
University of Miami Miller School of Medicine
Miami, FL
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
TQ

Tanya R. Quiroz

APRN
University of Miami
Hialeah, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
JB

Jovanna Bertran-Lopez

Assistant Professor of Clinical Medicine
University of Miami Miller School of Medicine
Miami, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
PR

Patricia Raccamarich

MD
University of Miami
Miami, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
EM

Emily K. Montgomerie

Research Associate
University of Miami, Miller School of Medicine
Cutler Bay, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
IB

Irma S. Barreto

Research Associate
University of Miami Miller School of Medicine
Miami, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Lilian M. Abbo

Professor of Infectious Diseases; Associate Chief Medical Officer in Infectious Diseases
University of Miami Miller School of Medicine, Miami Transplant Institute and Jackson Health System
Miami, FL
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
SD

Susanne Doblecki-Lewis

Professor of Clinical Medicine
University of Miami Miller School of Medicine
Miami, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
YW

Yanyun Wu

Transfusion medicine director
University of Miami Miller School of Medicine
Miami, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
MA

Maria L L. Alcaide

Professor
Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine
Miami, Florida
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Background: The Coronavirus disease of 2019 (COVID-19) global health crisis caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in unprecedented mortality, impacted society, and strained healthcare systems, yet sufficient data regarding treatment options are lacking. Convalescent plasma, used since 1895 for infectious disease outbreaks, offers promise as a treatment option for COVID-19.

Methods: This is a retrospective study of patients diagnosed by a nasopharyngeal swab SARS-CoV-2 reverse transcriptase–polymerase chain reaction (RT-PCR), who received convalescent plasma between April to June 2020 at two large hospitals in Miami, Florida, as part of the US FDA Expanded Access Program for COVID-19 convalescent plasma (CCP).

Results: A total of 23 patients received CCP, 13 (57%) had severe COVID-19 disease, while 8 (35%) had critical or critical with multiorgan dysfunction. Median time of follow up was 26 (range, 7-79) days. Overall, 11 (48%) survived to discharge, 6 (26%) died, while 6 (26%) are currently hospitalized. All deaths reported were due to septic shock from secondary infections. 15 (65%) showed improvement in oxygen requirements 7 days post CCP transfusion. Measured inflammatory markers, c-reactive protein, lactate dehydrogenase, ferritin and d-dimer improved 7 days post transfusion in 13 (57%) patients. No adverse events due to the transfusion were reported. 10 (43.4%) patients had a negative SARS-CoV-2 RT-PCR at a median of 14.5 (range, 4-31) days after receiving convalescent plasma.

Conclusion: Administration of convalescent plasma was found to be safe, with favorable outcomes in this small cohort of relatively high acuity patients. Larger studies including control arms are needed to establish the efficacy of convalescent plasma on clinical and virologic outcomes for patients with COVID-19.Table